Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Post by Stocktreeon Oct 05, 2016 3:51pm
72 Views
Post# 25313528

If anyone is considering filing a complaint to the IIROC

If anyone is considering filing a complaint to the IIROC
I will gladly join in. The NR is terribly incomplete. No data was provided except a very unexpected MB. No mention of placebo group M, treated group mortality, CM, non-consent group mortality, statistical analysis, the statistical discrepancy (non-consent M 62% vs placebo M 47,5% ??).

No hard data, just a : well it is certainly not for now folks, have a good day.

Also, the IIROC could have halted (maybe they never do, but they should), considering the lack of data provided and the subsequent debacle. The panic sell was a result of a complete loss of confience over Spectral's management, considering what had transpired this summer and at the September conference. I never thought top line data would look like it did. You can DD till the end of time, but if there is bad faith or gross incompetence on the part of the people sharing the data, you can only blindly hope everything is at it is. The trial was botched or something (mixup in canisters) or those in charge failed to monitor the patient composition to control factors : one I might think of is the fact that the non-consent subgroup was composed in a major way of people who had already been admitted for long periods in hospitals and their family did not think they had it in them to survive any treatment, and the randomized group was composed of patients that were unexpectantly admitted to the ICU and their family had a feeling they could benefit from what treatment they could get).

Off crying for now.
Bullboard Posts